Health Condition 1: D561- Beta thalassemia
Conditions
Interventions
Intervention1: L-Carnitine: 1000mg once a day for 6 months
Intervention2: N-acetyl-cysteine: 600 mg once daily for 6 months
Control Intervention1: placebo: once daily for 6 months
Sponsors
Dr Pragna Roy
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients with thalassemia on blood transfusion 2)Patients or legally authorized representative willing to give informed consent and assent for the trial.
Exclusion criteria
Exclusion criteria: 1) Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition of N-Acetyl-Cysteine and L-Carnitine 2) Patients with history of central nervous system diseases (like epilepsy, psychiatric disorder) or taking any medicine for such illness. 3) Patients with history of severe renal or hepatic disease (like hepatitis B or C) 4) Patients with history of bronchospastic diseases (like asthma) 5) Patients with history of hypothyroid disorder 6) Patients on warfarin or acenocoumarin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between N-Acetyl-Cysteine Vs L-Carnitine in the level of change in oxidative stress markers like MDA, GSH, SODTimepoint: Two years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Difference between N-Acetyl-Cysteine Vs L-Carnitine in liver enzymes, lipoproteins, cardiac biomarkers -2) Number of ADRs in arms of N-Acetyl-Cysteine and L-Carnitine Timepoint: Two years | — |
Countries
India
Contacts
Public ContactDr Waseem Rizvi
Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh
Outcome results
None listed